Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use

Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use Howard Ozer, Barry Mirtsching, Michael Rader, Susan Luedke, Stephen J. Noga, Beiying Ding, Lyndah Dreiling Oncologist 2007; 12: 484-494 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Describe the incidence of neutropenia-related endpoints when pegfilgrastim was administered in the first and subsequent chemotherapy cycles. Compare results with data reflecting current community practice standards. Discuss the relevance of pegfilgrastim use beginning in the first cycle of chemotherapy. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 30, 2007 Most Recent Review: Apr. 30, 2007* Most Recent Update: Apr. 30, 2007 Date Credit Expires: Apr. 30, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course